📢 #PortfolioNews Congratulations to Theolytics on the appointment of David Apelian MD, PhD, MBA as their new CEO. David is an experienced CEO and leader in the biotech industry who has worked across all phases of drug development. He joins at an important time for Theolytics, as they advance their first clinical trial in ovarian cancer. We look forward to supporting David and the Theolytics team as they continue their work to develop the next-generation of immunotherapies for the treatment of cancer. You can find out more about David here: https://lnkd.in/ePybPa6D #Biotech #Innovation
